Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
UA scientists aim to identify drug targets for rare pediatric cancer

UA scientists aim to identify drug targets for rare pediatric cancer

Rhabdomyosarcoma (RMS) is a rare cancer of the skeletal muscle that primarily affects pediatric patients. After diagnosis, about 3 out of 4 patients are cured with standard treatment. Survival rates drop to 17 percent if the disease comes back (recurs) and to 30 percent if it spreads (metastasizes).

“RMS has among the worst survival statistics for any solid pediatric tumor,” said Justina McEvoy, PhD, assistant professor of molecular and cellular biology at the University of Arizona, and member of the UA Cancer Center and the UA BIO5 Institute. “There is an urgent need to improve therapies for these kids.”

In response, scientists are eager to identify “precision” drugs that can target tumors directly. The most comprehensive assessment of RMS drug targets recently was published in Cancer Cell. Dr. McEvoy, who was a first author, joined the study when she was a postdoctoral fellow at St. Jude Children’s Research Hospital in Memphis, Tenn., and continued to contribute after joining the UA in 2014.

Dr. McEvoy describes a target as a key protein that a drug can attack.

“A target is a protein that instructs the cell to be cancerous. If we could shut that protein down, we could reverse or stop that process,” she said. “Rhabdomyosarcomas have very few druggable mutations, which makes developing treatments difficult.”

To find drug targets, scientists focus on genetic “signaling pathways,” which is a system to relay instructions from one end of the cell to the other to direct growth and division.

“Think of it as a phone tree, where a parent starts calling other parents, and those parents call other parents, and finally they execute a plan,” Dr. McEvoy said. “A signaling pathway ultimately turns on all the machinery needed for the cell to divide.”

Dr. McEvoy and her team sifted through a large genetic and protein database collected for rhabdomyosarcoma to identify pathways containing potential drug targets. They focused on a gene called WEE1, which codes for a protein kinase that regulates cell division and is particularly active in rhabdomyosarcoma. In lab experiments pitting drug candidates against RMS tumor cells, the team found one drug in particular, adavosertib, was especially potent against tumors expressing WEE1, particularly when combined with the chemotherapy drug irinotecan.

“When we combined irinotecan, the current therapy for RMS, with adavosertib, most of the tumors either had a complete or partial response, or stable disease,” Dr. McEvoy reported. “It was pretty effective compared to the standard treatment alone.”

Before adavosertib can be used in RMS patients, scientists must gather more evidence for its effectiveness. Dr. McEvoy’s former team at St. Jude is pushing that research forward. The team’s work also offers a jumping-off point for many additional paths in RMS research. At the UA Cancer Center, Dr. McEvoy is using the same datasets to branch off into her own research niche, focusing on molecules called “non-coding RNAs.”

“Non-coding RNAs are emerging as key regulators in tumor formation,” Dr. McEvoy said. “The work is challenging because nothing is really known about them in rhabdomyosarcoma, but it’s also exciting because it opens a new window of opportunity.”

The genetic code is a tangle of molecules that can be unwound to reveal the score for the symphony of life, each gene signifying a protein, or a note. But many genes don’t make proteins, resulting in a symphony with long periods of silence between movements. It turns out, however, that rather than playing notes, these genes might be conducting the orchestra, directing cells to play some notes at full blast while muting others.

Figuring out how non-coding RNAs function is a relatively new endeavor, and Dr. McEvoy is excited to learn more about how these mysterious sections of the human genome guide the growth of RMS cells, perhaps by activating some genes and deactivating others. Her lab is uncovering how one of the major mutations driving RMS is regulated by non-coding RNAs.

“When we deactivate the non-coding RNA, we can shut off the expression of that mutant gene, and cancer cells in a culture dish die. It’s pretty drastic,” Dr. McEvoy said. “Now we’re trying to understand what other genes and proteins might be regulated by these non-coding RNAs. Our goal is to find already-existing therapies to shut down those pathways.”

Dr. McEvoy knows that science is a marathon, not a sprint, and is motivated by her belief that the hard work ultimately will pay off.

“When I see the pieces coming together, when we can see the potential for therapeutic advancement — it is really rewarding,” she said.

Source:

https://uahs.arizona.edu/

Tagged with:

About author

Related Articles